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coklnetlc, and cllnlcal resplratory effects of 72-h appllcatlon
of two transdermal fentanyl (ITSF) patch slzes In patlents
undergolng abdomlnal hysterectomy.
Metbods:TlsF patches releaslng 50 pg/h (fTSB-iO) otTS ttg/h (TTSF.75) fenranyl or placebo patches were applled to 120
women 2 h before abdomlnal hysterectomy under general
anesthesla. Postoperatlvely, all patlents had access to supple.
mental morphlne uslng patlent-controlled analgesla pumps.
Each patlent was attended contlnuously by a research nurse
for 8 h on the nlght before surgery and for g4 h after patch
appllcatlon. The followlng data were collect€d: vlsual anatog
scale paln scores, supplementary analgesla, fentanyl ptasma
concentratlon (4.h Intervats), contlnuous hemoglobln satu.
ratlon (pulse oxlmetry), resplratory pattern (contlnuous res-plratory Inductlve plethysmography), and adverse effects(nausea, vomltlng, prurltus). Data analysls lncluded analysls
of varlance, Kruskal-Wallls, and chl-cquared. p < 0.05 was
consldered slgnlfi cant.
Resrrrrs.. There were no demographlc dlfferences among
groups. Vlsual analog scale paln scores were ilgntficantly
lower for the ITSF-75 group, and supplemental morphlne wai
slgnlhcantly decreased tn the TtSF.Tj group In the postanes-
thesla care unlt and for both the TTSF.50 and therITSF.TS group
for 8-48 h postoperatlvely. Between 5 and 36 h, the TISi
groups had slgnlffcantly Increased abnormal resplratory pat.
tern lncludlng apnelc eplsodes (tldal volume ofless than 100
ml for more than 15 s) and eplsodes of slow resplrarory rate(less than I breaths/mln perslstlng for more than 5 mtn) and
slgnlflcantly Increased requlrement for oxygen supplemen-
tatlon. Nlne patlents ln the TTSF groups were wlthdrawn be-
cause of severe resplratory depresslon compared to none ln
the placebo group. No slgnlflcant between-group dlfrerences
were pfesent ln the lncldence of nausea, vomltlng, or prudtus.
Although fentanyl plasma concentratlon was hlgher ln the
TTSF-75 group than ln the TTSF.5O group, the dlfferences were
no_t slgnlffcant. Fentanyl plasma concentratlon decr€ased slg.
nlffcantly 48 h after patch appllcatlon.
Conchtslotts: Appllcatlon ofTTSF patches 2 h preoperatlvety
ls assoclated wlth moderate supplementary oplold requlre-
ments for analgesla In the early postoperatlve perlod and on-
golng oplold supplementatlon for at least T2 h. Although good
analgesla ls the result of thls comblnatlon therapyt lt ls as.
soclated wlth a htgh Incldence of resplratory depresslon re-qulrlng lntenslve monltorlng, oxygen supplementatlon, re.
moval of the TTSF patches ln approxlmately 11% of the pa.
tl€nts, and oplold reversal wlth naloxone ln approxlmately
8% ofthe patlents. (Key words: Analgesla: patlent-controlledi
postoperatlvei transdermal dellvery. Compllcatlons: respha'
tory depresslon. Oplolds: basal lnfuslon; fentanyl. Paln: post'
operatlve. Ventllatlon' apnea: pattern.)
THE combination of the Transdermal Therapcutic
Systemr (fiS, Alza, PaloAlto, CA) with the lipid-soluble
synthctic opioid fentanyl provided a simple, effective
transdcrmal delivery system for a potent opioid anal-
gesic. The systcm controls release of fentanyl to pro-
vide n continuous and steady supply of the opioid
transdermally2 and maintains relatively predictable
plasmzt concentrations of fentanyl withottt invasive
proccdures or special cquipment.s The variation in pa-
tient metabolic clearance and stcady-statc volume of
distribution will determinc the resulting steady-state
plasma concentration in each subject. Drug delivery is
increased by increasing the size ofthe activc patch sur-
face as each square centimeter delivcrs npproximately
2.5 pg/h fentanyl. Thus, n 20-cm2 patch delivers 50
pg/hand a 30-cm2 patch T5 pg/h. Enrlier clinicnl stucl-
ics documented thc analgesic effectivencss of various
sizes of TTSF patches (e.g., 50,75, and 100 pg/h)
for the trcatment of postoperative pain aftcr orthope-
dic,4-8 urologic,e gynecologic,ro abdominal,r r-rt and
thoracic surgery.6 Most of these studics involved patch
applicatlon of 24h or lesswith a small numberof stud-
ies assessing patch use over longcr periods (up to 72
h). The choicc of administered dose should result in
fentanyl plasnra concentrations that irrc safe in all pa-
ticnts, i.e,, no risk of respiratory dcpression; this will
result in incomplete analgesic efficacy in some paticnts
because of pharmacokinetic variability. Thus, thc sup-
plemcntation of morphine (or other analgcsics) is a
fundamental component of the usc of transdcrmal fcn-
tanyl patch in somc patients. A common finding in pre-
vious studics was the requirclnent for supplementary
analgesics in addition to the TTSF patch in the post-
operative pcriod.r'l Despite using relatively low-dose
TTSF patches that often rcquired opioid supplcmcn-
tation, sevcral investigators still reported a relatively
low incidencc of clinically significant respirirtory
depression in the ir paticnts receiving 'I-ISF4'5'r I'r:t'r4 us-
ing mostly noncontinuous methods to measurc rcspi-
ratory depression. Thercfore, wc electcd to further in-
vcstigatc the use of the TTSF patch to dcline the inci-
dencc and scveriry of clinically significant respiratory
deprcssion with its use. Thus, this stuclywas undertaken
to evaluatc 50 and 75 FS/h TTSF used fot 72 h after
abdominal hysterectonry. Postoperative nnalgesia, sup-
plementary opioid requiremcnts using patient.con-
trolled analgesia (PCA), serial plasma fentanyl concen-
tration, and particulady intensive noninvasive con-
tinuous rcspiratory monitoring (pulse oximetry, respi-
ratory inductive plethysmography) were mcasured for
84 h after surgery to determine the analgesic effective-
ness and the respiratory effects of the TTSF patch.
Methods and Materials
Approval to carry out this study was obtained from
the Toronto Hospital and Ottawa General Hospital
Committees for Research on Hnman Subjects. All pa-
tients gave theirwritten informed consent to panicipate
before cntcring the study. The study was dcsigned to
be randomized, double-blind, and placebo-controlled.
Sample Slze Estlmatlon. Based on the results of
previous studics,a'r5 it was determlned that, in a three.
arm study comparing placebo, T|SF-50, and TTSF.75,
a sample sizc of 4O patients per group wonld provide
a type I error rate of 0.O5 and a type 2 error rate of
O.l (1,e,, powcr of 9O%) to detect a mean difference
in morphine usc of 6 mg during the pcriod from 12 to
24 h after TTS npplication. This difference applied to
comparisons between each of the two activc groups
and the placebo group.
Patient Selectlon. Patients schedulcd for abdominal
hystercctomy were included in the study. Incltrsion
criteria v/€rc nge 18-60 yr; ASA physical status I or 2;
body wcight 50-75 kg; no significant central nervous
system, respiratory, cnrdiac, hepatic, or renal dysfunc-
tion; no prcvions allcrgies or adverse reactions with
opioid analgesics; ancl no historyof opioid or substance
abuse.
Randomlzation and Bllnding Procedures. Pa-
tients werc randomly assigned to one of three groups,
placebo, TTSF-5O, or fiSF-75. Doublc-blinding was
aclrieved by applying two unmarked patches to cach
patient, one of TTSF-50 size and the other of fiSF-75
size . Active patchcs containing fentanyl were indistin-
guishable frorn placebo patches.
Preoperative Assessment. The night bcfore sur-
gery, patients were familiarized with the visual analog
scale (VAS) aud were introduccd to the PCA pump and
instructcd in its use. To provide baseline measurements
for postoperative respiratory assessment, all subjects
underwent n modificd slccp study for 8 h on the pre-
opcrative night. Respiratory pattern was assessed con-
tinuously with respiratory inductive plethysrnography
(NIMS, Miami Beirch, FL), and hemoglobin oxygcn sat-
uration (Sper) was continuously mensured using pulse
oximetry (Nellcor N-100, Nellcor, Hayward, Ca) while
patients slept. Calibration and validation of the respi.
ratory inductive plethysmograph-as well as its appli.
cation in previous postoperative analgesic studies-
have been described elsewhere,r('-18 Respiratory rate
(RR), episodes of apnea (tidal volume of less than 100
ml for more than 1 5 s) , and eplsodes of slow RR (SRR,
less than 8 breaths/min persisting for more than 5 min)
were measured continuously and recorded in 5-min
epochs. Patients were attended continuously by rained
personnel during the entire 8-h preoperative and 84-
h postoperative data collection periods. Respiratory
pattern abnormalities were confirmed by the analysis
of real-time respiratory inductivc plcthysmography
output and direct observation of the patienr. Revali-
dation (spirobag technique) was performed sevcral
times during the observation periods and recalibration
instituted if the error was greatcr thtn 20%.
Patch Appltcatlon. The patches were applied im-
mediately below thc clavicle on rhe right and left sides
of the upper chest approximately 2 h before surgery.
The time of patch application was takcn as time 0 for
all rncasurements.
Anesthesla. All patients received 10 mg oral diaze.
pam 2 h preoperatively. Anesthesia was induced with
sodium thiopental and maintained wlth 0.5 pg/kg su-
fentanil, o4ygen/nitrous oxide, and isoflurane plus
pancuronium for muscle relaxatlon. At the conclusion
of surgery, muscle relaxation was reversed with nco-
stigminc and atropine. rWith resumption of spontaneous
breathing, the trachea was extubated, and the patient
was transported to the postanesthesia care unit (PACU).
Po s t op erat lu e M an ag e tn en t
Supplementary Analgesla. The parches were left
ln sltu for 72 h after application. Patients were mon.
itored and data collected for thc full72 h period of
patch application plus an additional 12 h after patch
removal. Supplementary analgesia consisted of ob-
server-administered morphine boluses in the PACU and
PCA morplrine upon transfer to rhe ward. In the PACU,
if the patient spontaneously requested analgesia, a 2.
mg dosc of intravcnous morphine was given. In addi-
tion, at lO-min intervals, the patient wAs asked, "Do
you necd pain relief,/" If a positive response was given,
aZ-mg intravenous dose of morphine was administered.
The PCA pump (Abbott Life Care Infuser, Chicago, IL)
was set to dellver a l-mg bolus of morphine with a
lockout time of 5 min. The total dose of morphine re-
quired during the past hour was recorded hourly.
Postoperatlve Paln and Sedatlon Measurement.
A 10-cm VAS with 0 : no pain and 10 = worst pain
imaginable, was used to assess pain intensityat rcst and
with movement. Pain was measured every 4 h unless
the patientwas aslcep. Athree-point sedarion scnle was
recorded every 4 h unless the patient was aslecp (0 =
alert, oriented; 1 = drowsy, oriented; 2 = drowsy, dis-
oriented). No more than 8 h was allowcd to clapse
berween two consecutive measurements, which oc-
casionally rcquired waking the patienr.
Pharmacoklnetlc Analysls. Immediately before the
application of thc TTS patches and every 4 h postop-
eratively, venous blood samples were drawn from a
peripheral vein (ulaan indwelling heparinized cannula
where possible) for plasma fentanyl assay. Plasma fen-
tanyl concentrations were determlned with a commer.
cial radioimmunoassay kitte (fanssen, Beersc, The
Nethedands). In our laboratory, the assay is sensitive
to 0.1 ng/ml, with intraassay and interassay coefficients
of variation of 6.O% tnd 6.)%, respectively, at 1.0
nglml.
Postoperatlve Respiratory Monltodng. lVhen
the patienr arrived in the PACU, respiratory inductive
plethysmography and pulse oximetry monitoring was
reinstituted and continucd until the end ofthc study.
Oxygen supple mcntation routlnely was provided for
the first 2 h in the PACU and then discontinued. If,
at any time , respiration was judged to be inadequate
(RR < 8 breaths/min X 3 episodes/h) and/or he.
moglobin saturation was <90%, an arterial blood gas
sample was analyzed, If Spe, persisted at <90%, sup-
plementary oxygen was provided by face mask to
provide Spo, ) 9O%, The TTS system was removed if
RR was <8 breaths/min X 3 episodes/h for 2 con-
secutive h and/or Spe, was <9O% and Paqq, was >55
mmHg. Removal of the TTS patches terminated the
study for that patient. Respiratory monitoring, how.
ever, was continued for a further 12 h becausc of the
fentanyl depot that develops intradermally with the
TTS system and continues to maintain a plasma fen-
tanyl conccntration.2 In the event of severe respira-
tory depression, naloxone was administered as re-
quired.
Adverse Effects. Nausea and vomiting werc treatccl
as needed with 25-50 mg inrravenous diphcnhydra-
mine and/or 1 mg intravenous droperidol. Pruritus
was treated with 50 mg intravenous diphenhydra-
mine as needed. T'IS attachment sites were assessed
at regular intervals and at the time of removal for
skin reactions.
Table 1. Patlent lvlthdrawal: Resplratory Depresslon
ASs (yr)
Naloxono
(ms)
Wolghl
(ks)
Removal
rrs (h)
Morphlne
(ms)
Plasma Fentanyl
(ns/ml)
pacq
(mmHg)
TTSF-s0
TTSF-50
fisF-50
TTSF-75
TTSF-75
TTSF-75
TTSF-75
TTSF-75
TTSF-75
45
50
57
37
52
52
42
37
45
64
60
63
66
59
72
7A
51
54
10
7
16
32
6
c
11
7I
47
4
23
't9
14
16
36
10
22
1.35
2.19
'1.64
2,23
1.90
N/A
0.93
1.10
1.58
0.05
0
0.1
0
0
0.04
0
0.2
0.51
56
56
58
51
N/A
58
56
60
59
RemovalTTS (h) = duratlon of TTS-palch before removal and wlthdrawal lrom study; Monhlne (mg) = total dose of supplemental morphlne bsfore wlthdrawal from
study; Plasma F€ntanyl (ng/ml) = plasma fentanyl concentratlon at tlmo of wlthdrawali Natoxone (mg) = totat dose of naloxone admlnlst€red; paco, (mmHg) =
arterial Pcor 8t tlme of wlthdrawal; TTSF-So = fiS-fentanyl 50; TTS-75 = TTS-fentanylT5; N/A = no blood sample.
Data Anab)sls
Data are summarized as their mean value t SEM (for
parametric data) and as frequencies or percentages (for
nonparametric variables) and were analyzed using one-
way analysis of variance (ANOVA, e,9,, demographic
data) or chi-squared tests ofsignificance, respectively.
Data amenable to repeated-measures ANOVA (pain in.
t€nsity at restt pain intensity with movement, supple-
mentary morphine , vital signs) were analyzed over time
(in 4- or 12-h blocks) using treatmenr group and study
site as factors, followed by linear contrasts or Tukey's
test to compare pairwise differences when the overall
ANOVA was significant. Overall apnea rate and SRR/h
were analyzed using a one-way ANOVA for the entire
84-h period and again between 5 and 36 h postoper-
atively. rf(/hen the overall ANOVA demonstrated a sig-
nificant group effect, Tukey's test was used for pairwise
comparisons between the groups. Nonparametric data
were analyzed using chi-squared, with study site as
stratum, or Fisher's exact test, whcn necessary, The
strength of the linear relationship berween plasma fen-
tanyl concentration and respiratory parameters (mean
RR, SRR/h, apnea rate) was evaluared by computlng
Pearson product moment correlation cocfficients (r)
for each group evcry 4 h after surgery. A simple com.
parison ofaverage plasma fentanyl concentration across
two periods,23-48 and 52-72 h, was made for each
dosing group, using the patred t tesr. P < 0.05 was
considered statistically significant for all tests.
Results
Pattent Wtbdrawals
One hundrcd twenry patients were enrolled in the
stndy, with 103 patients completing the study. Sev.
enteen patients were withdrawn for the following rea-
sonsr Two patients did not undergo scheduled surgery,
and the TTS patches were removed within 6 h of ap-
plication with no adverse effects. One patient receivcd
10 tim€s the protocol dose of sufentanil intraopera-
tively and subsequently required removal of the TTS
patch (3 h after application) and multiple doses of
naloxone because of respiratory depression. Of the re-
maining l4 patients, 2 were withdrawn because of fail-
ure of respiratory monitoring equipment, 1 patient be-
came frustrated with the respiratory monitoring reglme
and rsithdrew, I patient removed her patches 29 h
after application, 1 patient developed pneumonia and
was withdrawn, and 9 patients were withdrawn from
the study because of respiratory depression (table l).
Six of the nine patients withdrawn because of respi-
ratory depression werc in the TTSF-75 group. The data
from these 14 patients were included in all analyses
up to the times at which they were withdrawn.
Demograpbic and Cllntcal Data
There were no significant differences between the
three groups with respect to age (33-36 yr), weight(61-64 kg), duration of anesthesia (l 12-t 15 min),
or duration of PACU observarion period (169-tS4
min).
Postoperatlue Paln
Overall, VAS pain scores were significantly less for
the TTSF-75 group at rest (P = 0.03) and with move-
ment (P = 0.04) compared with the placebo group,
but the TTSF-50 group did not dlffer significantly from
the placebo group for either rest or movement pain,
VAS paln scores were high in the early postoperative
period for all three groups (fig. 1). There was no sig-
nlficant difference between VAS pain scores ar rest or
with movement wltbln each of the three groups.
Postopemtlue Morpblne C onsumptlon
PACU. The mean total observer-administered mor-
phine requirements in the PACU was significantly less
(P = 0.04) in the TTSF.75 group compared with the
placebo group (TTSF-75 17.0 t 1.4 mg, TTSF.5O lS.4
t 1.4 mg, placebo 2l.9 + 1 .7 mg). Although the TTSF
groups required less supplemental morphineper bour
in the PACU than did the placebo group, this difference
was only significant for the TTSF.75 group during the
3rd hour in the PACU (fie.2).'
Ward. The mean total PCA morphine requirernents
on the ward were significantly less for both TTSF groups
(TISF-75 39.2 + 7. I mg, TISF-50 42.6 + 6,4 mg, pta-
cebo 72.5 x.6.) mg; P = 0.001, TTSF-75, TTSF-5O as.
placebo). Similarly, the total postoperarive supple-
mental morphine requirements (PACU * ward) were
significantly less for the TTSF groups compared with
placebo (TTSF-75 56,7 x.7.9 mg, TTSF-50 61.2+ 6.7
mg, placebo 94.4 + 7.7 mg P = 0.0008, TTSF.75,
TTSF-50 as. placebo). Between 8 and 48 h postoper-
atively the TTSF groups used significantly less morphine
than tlre placebo group (frg.2).
Resplratory Monltorlng
There was no difference in the mean hourly apnea
rate or in the mean number of episodes of SRR/h among
0t2243648607284
Tlme after TTSF appllcailon (h)
Flg. 1. Mean vlsual analog scale paln scores at rest. Overall,
the TTSF-75 group scores were slgnlficantly lower than those
ln the placebo group, but the TrSF-50 group scores dld not
dlffer from the placebo group scores. Ihe downward.polntlng
arrow lndlcates removal of the fiSF patch.
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Flg._2. Mean patl€nt.controlled (pCA) morphlne consumptlon
ln the postanesthesla care unlt (PACU) and on the ward. Thedownwardlolntlng arrow lndlcates removal of the TTSF
patch. rP< 0.O5, placebo rrelsrrs TTSF-75. tp < 0.05, ptacebo
uersns TISF-50 and TTSF.75.
the groups for the 8-h preoperative monitoring period
(figs, 3 and 4) . However, the apnea rate between 5 and
36 h after patch application was signlficantly higher
for TTSF.75 group compared with the placebo grogp
but not when compared with the TTSF-50 group (p =
0.006; fig. 3). In addition, within thts period, the three
groups ditrered significantly in the number of patlents
with mean hourly apnea rarc of < 1 or > I 0 (p < 0,006).
Only 2 patients in the placebo group had a mean hourly
apnea rate of >1.0, whereas 28 patients had a mean
hourly apnea rate of <1. In contrasr, 12 patients in the
TTSF-75 group had a mean hourly apnea rare of >10,
and L7 patients had a mean hourly apnea rate of <1.
TWenty-one patients in the TTSF.50 group had a mean
houdy apnea rate of <1., and 6 had a mean hourly apnea
rate of > 10. Similarly, there was a significant dlfference
between the TTSF-75 and TTSF.50 groups compared
with placebo in the mean hourly number of episodes
of SRR berween 5 and 36 h (p = o.005; fig. 4). Sig-
nificantly more patients in the TTSF-75 group had a
mean of 3 or more SRR episodes/h (placebo n = 5,
fiSF-75 n = 22i P = 0.003). Sixteen parients in the
TTSF-50 group had a mean of 3 or more episodes of
sRR/h,
The number of patients requiring supplementary ox-
ygen according to study crireria was significantly dif-
ferent for the three groups (P < 0.001; ng. 5). Signif-
icantly more patients in the TTSF-75 group (n = 25)
received o)qygen supplementation when compared with
the TTSF-50 (n: 12) and the placebo group (n = 7),
t
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Flg. 3. Mean apnea/h (apnea = 15 s * Vt < 100 ml). Between
5 ard 36 h, mean apnea/h In the TTSF.75 group was hlgher
than ln the placebo group (P< 0.006). The downward.polntlng
arrow Indlcates removal of the ITSF patch.
Oxygen supplementation wfls not necessary after 48 h
(fig. 5). Significantly more patients in the TTSF groups
required arterial blood gas sampling compared with
the placebo group (placebo n = 12, T'fSF-50 n = 24,
TTSF-75 n = 25; P = 0.04), and mean Pa6o, was sig-
nificnntly different in the TTSF-75 group compared with
placebo (TTSF-75 Pxcoz = 47 + L, placebo Pas6.= 42
+ 1; P = 0.04). There were no patient withdrawals
due to adverse respiratory events in the placebo group,
but three and six patients were withdrawn from the
T'ISF-50 and TTSF-75 groups, respecrively, because of
severe respiratory depression. Patient withdrawals for
severe respiratory deprcssion in thc TTSF groups oc-
curred within 5-32 h after patch application (table
1). Naloxonc for respiratory deprcssion rcversal was
not required for any patient in the placebo group,
whereas two patients in the TTSF-5O and three patients
in the fiSF-75 group were rreated with naloxone (ta-
ble 1),
Aduerse Efects
There was no significant difference in the incidence
of adverse effects (nausea and/or vomitingr placebo n
= 19, TTSF-50 n = 23, TTSF-75 n = 23i pruritus: pla.
cebo n = 4, TTSF-50 fr = 2,TISF-75 fi = 5; p = O,4).
P b artna co klne t I c Analy sl s
Eight hundred five blood samples (fiSF-50 n: 434,
TTSF-75 n = 371) were analyzed for fentanyl concen-
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Flg. 4. Mean.houdy number of 5-mln eplsodes of slow respl-
ratory r-ate (SRR, <8 breaths/mln for 5 mtn). There were slg-
nlffcantly more eplsodes of SRR/h tn the II5F.50 and TTSF-75
groups compared wlth the placebo group between 5 and 36 h(P = O.05). The downward-polntlng arrow lndlcates removal
of the TTSF patch.
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Flg. 5. Number of patlents recelvlng supplem€ntary oxygen
ln group ITSF-75 was slgnlficantly greater than the TTSF-50
or placebo groups (P < 0.001). Supplementary oxygen was
started and artedal blood gas drawn lf resplratory rate wa6
<8 breaths,/mln and/or Sae. was <90%, The downward-polnt.
lng arrow lndlcates removal of the TTSF patch.
tration. Plasma fentanyl concentration reached a rela-
tively steady-state by approximately 16-2O h after
patch application for both the TISF-75 and the TTSF-
50 group (fig. 6). In general, parients wirh the 75-pg/
h patches had higher plasma fentanyl conc€ntratlons
than did patients with the 50-p.g/h patches, although
the difference between the groups was not significant.
Plasma fentanyl concentration was significantly lower
during the 3rd day of patch applicarion compared wirh
the 2nd day for both TTSF groups (mean plasma fen-
tanyl concentration: TISF.5O 28-48 h = 1.15 + 0.1 1
nglml, 52-72 h = O.77 t 0.09 nglml (P = 0.0001);
TTSF-75 28-48 h = 1.56 + O.20 ng/ml, 52-72 h =
1,06 + 0.11 nglml (P = 0.004)). The change in mean
plasrna fentanyl concentration represents a 3j% de-
crease from the mean plasma fentanyl concentration
on the 2nd day. Area under the curve, 0-S4 h (trape-
zoidal rule, mean data) for TTSF-75 was 103.9
ng. h . ml-r ancl for TTSF-5O was 76. 1 ng . h . ml-t. The
ratio of area under the curvc, TTSF-75:fiSF-50, is 1.4.
Figure 7 shows the correlation coefficlents between
plasma fentanyl concentration and mean RR, SRR/h,
and mean hourly apnea rare for the T[SF-75 and TTSF-
50 groups on a 4-houdy basis after surgery. rVith the
exception of a few time points, there was no significant
linear relationship between plasma fentanyl concen-
tration and respiratory parameters. \flhen Bonferroni's
rype f error rate correction for multiple correlation
coefficients (1.e., a = 0.05/number of tests) was used,
no correlation coeftcient reached statlstical signifi-
cance. These graphs indicate that, when data from all
patients are used, there is no tendency for plasma fen-
tanyl concentrarlon to be significantly correlated with
the three respiratory parameters.
Discussion
This study demonstrated that the TTSF patch (50-75
pg/h) provides dose- and time-dependent analgesic ef.
ficacy to patienrs undergoing abdomlnal hysterectomy.
As in other studies, wc found a reduced ongoing need
for PCAsupplementatlon in the TTSF groups. However,
o12243648607284
Tlms after TTSF appllcatlon (h)
Flg. 6. plasma fentanyl concentratlon by radlolmmunoassay
method. Mean plasma fentanyl concentratlon between 52 and
72 h was slgnlficantly lower than the mean plasma fentanyl
concentratlon between 28 and 48 h for both ITSF groups. The
downward.polntlng arrow lndlcatcs removal of tha TTSB
patch.
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the respiratory depression observed was of a significant
degree and gave rise to concern about patient welfare,
in contrast to observatlons made with PCA alone.
The TTSF patch is a slow-onset, easy-to-use, nonin-
vasive transdermal infusion device that produces
plasma concentrations similar to those achieved with
an intravenous infusion of fentanyl.2,3 The plasma con.
centration of fentanyl will be related to the degree of
analgesia produced and the production of adverse ef-
fects, but in individual patients, analgesla and other
opioid effects are modified by other factors, such as
age, indivldual sensitivity, concomiant medications or
other interventlons, and undedying disease states. Fen.
tanyl, like all opioids, has a relatively restricted ctini-
cally useful dose-response range that can be defined as
the range between the minirnally effective analgesic
concentration (MEAC) and the highest tolerable anal-
gesic concentration before the production ofsignificant
respiratory depression,2o Several studies using pCA or
fentanyl infusions showed the MEAC for fentanyl to vary
berween 0.6 and 1.7 ng/ml.r8'2r-2t lndividual patients,
however, will vary in MEAC requirements over as much
as a sixfold range,2a,26 Clinically significant respiratory
depression was measured in similar studies with plasma
fentanyl conccntrations of 1-3 ng/m1.2'27-2e
P b armac oklnetlc Analy sls
The peak plasma concentrations produced byTTSF"50
and TISF-75 patches in this study are similar to those
described in other TTSF patch studies.3'a'6-8'rr'r3'3o 'Ihis
report is the first large study to report pharmacokinetic
data wlth a TTSF patch ln place for 72 h, Mean fentanyl
plasma concentration is significantly lower on the 3rd
day (52-72 h) compared with the 2nd day (28-48 h)
for both TTSF groups, indicating that both the 5}-p.g/h
and the 75-p.g/hpttch did not provide steady.state plasma
fentanyl concentration after 2 dap ofapplication. In the
current study, although mean plasma fentanyl concen-
tration was within the therapeutic range between 14 and
48 h after patch appltcation, mosr parients ln the TTSF
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groups required PCA morphine supplementation for sat-
lsfactory analgesia.
Postoperatlue Analgesla and Morpb{ne
Supplen entatlon
A clear disadvantage of the fiSF system is the slow
development of effective plasma concentration. Thus,
in this study in which the TTSF patches were applied
2 h preopcratively and only modest doses of intra-
operative optoid were admlnlstered, high patn scores
and high morphine requirements were seen in the im-
mediate postoperative period in the PACU for all three
groups (figs. 1 and 2). At 12 h postoperatively, PCA
morphine requirements for the TTSF groups were
markedly decreased, reflecting fentanyl plasma con-
centration approaching analgesic concentrations. The
placebo group (PCA only) maintained greater mor-
phine requirements for the full 84 h. In addition, the
placebo group characteristically did not achieve VAS
scores less than 3O% of maximum VAS. This finding is
similar to what other studies found \ilhen patients use
PCA.3r"12 Other investigators reported similar findings
to those found in this study, 1,e.,lower VAS scores (es.
pecially in those studies using 5o-100-pg/h TTSF
patches){'5't2'ra'r5 and lower opioid supplementation
in the TTSF groups.a't'r2'14'r5'31 It is significanr to note
that the majority of the subjects in these srudies and in
1 ours reguired opioid supplementation despite the ap-
plication of a TTSF patch.ra
Resplratory Efects
The rationale for the use of noninvasive continuous
electronic monitoring systems to measure respiratory
pattern and pulse oxlmetry in postoperatlve analgesic
studies was documented elsewhere3a and validated in
studies from our group and others.la'r7'r8'3r't<t 1n ggn.
eral, the system provides a nondisturbing mechanism
of obsewing and recording clinically significant respi-
ratory depression in the clinical setting.sT The use of
a nondisturbing system to measure respiratory pattern
and hypoxemia allows study of the postoperative pa-
tient in a setting as close to real life as possible. Other
useful techniques to measure opioid-induced respira.
tory depression, such as carbon dioxide-response testsr
produce alertness and arousal that alter the conditions
normally found in the postoperative patlent. Catley et
a/,36 showed correlation between changes in ventilatory
pattern and episodic oxygen desaturation when opioid
analgesics are used postoperatively, thus demonstrating
noninvasive monitoring techniques to be useful indi-
cators of resplratory risk. In this study, we observed a
dose.dependent increase ln the apnea rate and episodes
of SRR/h for each group as the dose of TTSF was in-
creased (figs. 3 and 4). In addition, the number ofpa-
tients with significant apnea rates, SRR episodes, and
hypoxemla (/.e., requiring supplementary oxygen) ln-
creased significantly as the dose of TTSF was increased
(ng. 5). Similarly, the number of patients requirlng
arterial blood gas analysis (on the basis of the criteria
outlined above) was significantly greater among pa-
tients in the TTSF groups. The development of carbon
dioxide retention increased as the dose of TTSF was
increased (table 1). None of the patients in the three
groups had evidence ofsleep apnea or respiratory pat.
tern abnormalities from the preoperative monitoring
results. It was significant that 9 of 80 (11.3%) of the
patients in the TTSF groups were withdrawn because
of increasingly severe respiratory depression, On the
basis of the findingp in this study and in others,r7,rtr'3t-37
noninvasive monitoring systems of respiratory functioh,
when coupled with pulse oximetry, provide as good
an indicator of risk of respiratory depression in the
clinlcal setting as is currently possible.3d
Respiratory depression following the use of the TTSF
patch has not been examined syst€matically. Several
investigators reported a low incidence of moderate to
severe respiratory depression in previous stud-
i"r.4'5'z' I o' I l' l'1' t 4 "18 Respiratory depression was defined
as RR < 8-10 breaths/min for the maiority of these
studies, and RR was measured intermittently. Exclusion
of continuous monitoring, especially hemoglobin sat.
uration! in these studies (table 2) may lead to under-
estimation of the incldence of clinically significant re-
spiratory depression. However, even in these earlier
studies, an incidence ofrespiratory depression, as de-
fined by the authors, of approximately l0% was seen
in many of them in the groups receiving transdermal
fentanyl (table 2). A significant feature of the currenr
findings was the relative restriction of respiratory
depression to the 5-36-h period postoperatively. The
occuffence of respiratory depression within this period
corresponds with reports of other investiga-
tors.4'5'7'ro'rr'l'r'3tl The mechanism of the respiratory
depression in the current study probably is related to
the slow development of analgesic plasma concentra.
tions of fentanyl with the TTSF system and the require-
ment for larger doses of morphine in the PACU to con-
trol early postoperatlve pain. The additive effects of
the rwo opioids and the contlnuing PCA morphlne re.
quirements are the most probable reason for the dose-
Table 2. Transdermal Fentanyl: tlve Studles-Resplratory Depresslon
lncldence
Study Aotlve (Slze) Descrlptlon Treatmont
Bormann (1988)E
Duthle (1988)tg
Gourlay (1989)"
Caplan (1989)'
Latasch (1989f
Boerner (1 991)38
Sevarino (1992)ro
Sandler (1994)
1120 (75't
2/e (1 00)
3/13 (50-125)
3122 (751
1/30 (75)
2/12 (60)
2ls2 (251,3/32 (50)
3/37 (50), 6/3e (75)
,:
0tzg
0/30
ol12
ol32
0/36
SRR (ward)
SRR (ward)
SRR (ward)
SRR (ward)
Hypoxia/hypercapnia
Not described
sRR (PACU)
AP (PACU/ward), SRR (PACUiward),
hypoxialhypercapnia
1 patlentr naloxone, TTS removed
TTS removed
1 patient naloxonel 2 patlents: oxygen
(mask)
Patlents aroused
No treatment
Unknown treatment
1 patlent naloxone
fiS removed, oxygen (mask)
(2/TTS-50), naloxone
(3frTS-75), naloxone
Incldenco = number ot patlents wlth cllnlcally slgnlficant resplratory depresslon ln each group: Actlve = TTs-fentanyl group; Slze = TTs-fentanyl patch slzei placebo
= placebo TTS group; lreatmont = lrsatment tor resplratory depresslon: SRR = slow respkatory rat€; ward = abnormal rssplratory patt€rn on wardi PACU =
abnormal resplratory paltem ln poslan€sth€sla care unll; AP = apnolc eplsodos,
related increase in respiratory abnormalities and in-
creased requirement for oxygen supplementation seen
in the TTSF groups up to 36 h postoperatively. The
decrcase in respiratory depression after 36-48 h prob.
ably is related to thc decrease in plasma fcntanyl con-
centration at this time (fig. 6).An analysis of pharma.
codynamic relationships between plasma fentanyl con-
centration and mcan RR, SRR, and apnea revealed no
correlation between any of the three respiratory pa.
rameters and plasma fentanyl concentration ar any timc
when blood was sampled for plasma fentanyl (fig. 7).
This indicates the high degree of variability in the oc-
currence ofrespiratory depression in the clinical setting
due to factors discussed abovc and the difficulty in as-
signing a plasma fentanyl concentration at which re-
spiratory deprcssion occurs in the individual patient.
Thns, it is possible that, in the postoperative period,
for thc individual patient, there may be as large a vari-
ability in plasrna fentanyl concentration producing
clinically significant respiratory depression as there is
for the MFAC.24'2(' This study also clocumcnted the rel-
ntive safety of PCA morphine alone (placebo group)
in tcrms of respiratory patrern and postoperative hy.
poxernia, although minimal alterations in these pafam-
eters v/efc prescnt secondary to postsurgical and an.
esthetic effects.le'a(l The incidence of scvcre respiratory
depression whcn opioids are administered by other
routes is rnuch lcss than the 1l% incidence found in
thc current study. For example, the incidence of re-
spiratory dcprcssion with intramuscular administration
of opioids is approximately O.)%4t and forspinal opioid
administration is 0.2-0.3 6y".42 ln a large retrospective
study, the incidence of sevcre respiratory depression
in patients using PCA was 0.5%,4.1
Most investigators found that the fiSF patch requires
analgesic supplementation to provide effective pain
relief, and thc majority of studies used opioids as the
supplemcntary analgesic agent. Howcver, in the one
study to datc that used a nonsteroidal antilnflammatory
drug as the supplementary analgesic agent, the inci-
dence of respiratory depression (Tpa66,, IRR) was low
despite the use of a7S-pg/hTTSF patch.T Similarly, in
another study using the TTSF-75 patch in 50 patients,
no clinically significant respiratory depression (lRR)
was recorded when fentanyl was used as the supple.
mentary analgesic.aa Both of these studies had the patch
applied for 24 h only, and therefore, scrum fentanyl
concentration would have decreased after 24 h and
would not summate with supplementary analgesic
therapy to produce respiratory depression.
In conrrasr to early reports4'8'e'tt that hailed the TTSF
patch as a major analgesic brcakthrough for acute pain
management, we conclude that the high incidence of
respiratory depression under the conditions of the cur-
rent study requires the TTSF system to be used only
under closely monltored conditions for acute postop-
erative pain with resuscitation facilities closc at hand.
This applies to the small number of patients who will
be able to usc the TTSF patch as a sole analgesic system
but will be particularly applicable if opioid or sedative
supplementntion is necessary. Thus, we do not rec-
ommend thc routine use of the TTSF patch for acute
pain control unless the above stipulations are met.
Neverthcless, th€ TTSF system has several maior advan-
tagcs (e.9., ease of use, high paticnt acceptability, in.
creased analgesic effectiveness, nonlabor-intensive)
that warrant furthcr study to characterize other possible
uses. Investigation into thc use of the TTSF patch as a
component of a multimodal analgesic system (1,e., in
coniunction with an a agonist and a nonsteroidal an-
tiinflammatory drug) may provide an effective post-
operative analgesic regimen. In addltion, in the treat.
ment of chronic cancer pain, the advantages of the TTSF
patch combined with the system's sustained drug re-
Iease profile make it useful. This is evidenced by the
fact that TTSF is used as a highly effective analgesic for
chronic cancer pain and is approved for this usc in
several countries.
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